News | April 17, 2012

Japan Clears Abbott Xience Prime Drug-Eluting Stent

April 12, 2012 – Abbott announced approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation Xience Prime Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE PRIME, which uses the same drug and biocompatible polymer as the XIENCE V Everolimus Eluting Coronary Stent System, features an enhanced stent design and a delivery system designed for greater flexibility, ideal radial strength, excellent longitudinal strength and more accurate stent placement. With this approval in Japan, XIENCE PRIME is available in all of the major markets worldwide, including the United States, Europe, China, India and other countries in the Asia-Pacific and Latin America regions.

"New stent technologies such as XIENCE PRIME play an important role in enhancing the care we provide to patients in Japan who have coronary artery disease," said Takaaki Isshiki, M.D., Division of Cardiology, Teikyo University Hospital. "XIENCE PRIME retains many of the features that have made XIENCE V an important treatment option for patients, and incorporates improvements that will enhance our ability to access challenging and complex lesions. Importantly, XIENCE PRIME includes a broad size matrix and is the only everolimus eluting coronary stent in Japan with long-length stent sizes of 33 mm and 38 mm."

XIENCE PRIME is based on the stent design of the MULTI-LINK family. It utilizes cobalt chromium technology and features a "peak-to-valley" mechanical design that imparts longitudinal strength and stability to the stent. XIENCE PRIME features one of the thinnest drug eluting stent struts available while maintaining radial strength to support the vessel, and it provides excellent visibility under X-ray during stent implantation procedures. XIENCE PRIME is offered in lengths up to 38 mm to treat long lesions.

"XIENCE PRIME leverages the best of XIENCE V, which is the market-leading drug-eluting stent in Japan and throughout the world, and the introduction of XIENCE PRIME further advances Abbott's leadership position," said Robert B. Hance, senior vice president, vascular, Abbott. "We are pleased to offer this next-generation technology to physicians for the treatment of their patients in Japan, the second-largest healthcare market in the world. XIENCE PRIME is supported by a robust body of clinical evidence, as the XIENCE family of stents has been studied in more than 100 trials in more than 45,000 patients."

Approval of XIENCE PRIME in Japan was supported by results from the SPIRIT PRIME clinical trial, a prospective, open-label trial that evaluated XIENCE PRIME in approximately 500 patients with coronary artery disease. The trial met its primary endpoint, with low rates of target lesion failure (TLF) at one year. Stent thrombosis rates at one year also were very low (0.5 percent), with all cases occurring within 30 days and no cases of stent thrombosis reported in patients treated for long lesions.

For more information: www.xiencestent.com

Related Content

Abbott has pulled the Absorb Bioresorbable scaffold stent off the market.

The biggest cardiac technology story in September was Abbott pulled the Absorb Bioresorbable scaffold stent off the market because poor sales.

Feature | October 02, 2017
October 2, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardi
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
Overlay Init